Search

Your search keyword '"Guillerm G"' showing total 294 results
Start Over Author "Guillerm G"
294 results on '"Guillerm G"'

2. Late relapse after hematopoietic stem cell transplantation for acute leukemia: a retrospective study by SFGM-TC

Author

Kaphan, E., primary, Bettega, F., additional, Forcade, E., additional, Labussière-Wallet, H., additional, Fegueux, N., additional, Robin, M., additional, De Latour, R. Peffault, additional, Huynh, A., additional, Lapierre, L., additional, Berceanu, A., additional, Marcais, A., additional, Debureaux, P.E., additional, Vanlangendonck, N., additional, Bulabois, C.-E., additional, Magro, L., additional, Daniel, A., additional, Galtier, J., additional, Lioure, B., additional, Chevallier, P., additional, Antier, C., additional, Loschi, M., additional, Guillerm, G., additional, Mear, J.B., additional, Chantepie, S., additional, Cornillon, J., additional, Rey, G., additional, Poire, X., additional, Bazarbachi, A., additional, Rubio, M.T., additional, Contentin, N., additional, Orvain, C., additional, Dulery, R., additional, Bay, J.O., additional, Croizier, C., additional, Beguin, Y., additional, Charbonnier, A., additional, Skrzypczak, C., additional, Desmier, D., additional, Villate, A., additional, Carré, M., additional, and Thiebaut-Bertrand, A., additional

Published
2023
Full Text
View/download PDF

3. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC

Author

Tessoulin, B, Ceballos, P, Chevallier, P, Blaise, D, Tournilhac, O, Gauthier, J, Maillard, N, Tabrizi, R, Choquet, S, Carras, S, Ifrah, N, Guillerm, G, Mohty, M, Tilly, H, Socie, G, Cornillon, J, Hermine, O, Daguindau, É, Bachy, E, Girault, S, Marchand, T, Oberic, L, Reman, O, Leux, C, and Le Gouill, S

Published
2016
Full Text
View/download PDF

4. Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin’s lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC)

Author

Stamatoullas, A, Brice, P, Gueye, M S, Mareschal, S, Chevallier, P, Bouabdallah, R, Nguyenquoc, S, Francois, S, Turlure, P, Ceballos, P, Monjanel, H, Bourhis, J-H, Guillerm, G, Mohty, M, Biron, P, Cornillon, J, Belhadj, K, Bonmati, C, Dilhuydy, M-S, Huynh, A, Bernard, M, Chrétien, M-L, Peffault de Latour, R, and Tilly, H

Published
2016
Full Text
View/download PDF

5. Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

Author

Mamez, A-C, Lévy, V, Chevallier, P, Blaise, D, Vigouroux, S, Xhaard, A, Fegueux, N, Contentin, N, Beguin, Y, Ifrah, N, Bulabois, C-E, Suarez, F, Yakoub-Agha, I, Turlure, P, Deconink, E, Lamy, T, Cahn, J Y, Huynh, A, Maury, S, Fornecker, L M, Ouzegdouh, M, Bay, J-O, Guillerm, G, Maillard, N, Michallet, M, Malfuson, J-V, Bourhis, J-H, Rialland, F, Oumedaly, R, Jubert, C, Leblond, V, Boubaya, M, Mohty, M, and Nguyen, S

Published
2016
Full Text
View/download PDF

7. Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

Author

Largeaud, Laetitia, Cornillet-Lefebvre, Pascale, Hamel, Jean-François, Dumas, Pierre-Yves, Prade, Naïs, Dufrechou, Stéphanie, Plenecassagnes, Julien, Luquet, Isabelle, Blanchet, Odile, Banos, Anne, Béné, Marie, Bernard, Marc, Bertoli, Sarah, Bonmati, Caroline, Fornecker, Luc Matthieu, Guièze, Romain, Haddaoui, Lamya, Hunault, Mathilde, Ianotto, Jean Christophe, Jourdan, Eric, Ojeda, Mario, Peterlin, Pierre, Vey, Norbert, Zerazhi, Hacene, Yosr, Hicheri, Mineur, Ariane, Cahn, Jean-Yves, Ifrah, Norbert, Récher, Christian, Pigneux, Arnaud, Delabesse, Eric, Marolleau, J.-P., Aleme, A., Orsini-Piocelle, F., Cadoux, N., Marie, C., Al Jijakli, A., Lepeu, G., Beyrne, M., Labarrere, S., Deconinck, E., Peria, M., El Yamani, A., Kadiri, O., Choufi, B., Brument, M., Leguay, T., Berthou, C., Guillerm, G., Drugmanne, G., Tournilhac, O., Roy, G., Audhuy, B., Camara, S., Caillot, D., Grandjean, M., Bulabois, C.-E., Fief, B., Ladraa, C., Dorvaux, V., Hagopian, M., Fegueux, N., Fenoll, C., Sabadash, V., Haby, C., Witz, F., Lhuire, M., Delaunay, J., Airiau, L., Mannone, L., Touitou, I., Umuhire, D., Alexis, M., Michel, O., Dreyfus, F., Bouscary, D., Cheung, A., Sanhes, L., Touhami, F., Ribas, E., Puyade, M., Gallego-Hernanz, M.-P., Hugon, N., Himberlin, C., Maggi, L., Lamy, T., Testu, A., Tavernier, E., Marchand, S., Lioure, B., Kravanja, C., Benboubker, L., Nollet, D., Attal, M., Sarry, A., Lhermitte, A., Yrica, G., Schwartz, D., Le Montagner, N., Auvray, L., Delepine, R., Fayault, A., Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service d'Hématologie Biologique [Hôpital Robert Debré, Paris], AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), CHU Bordeaux, Service d'Hématologie Clinique et Thérapie Cellulaire, F-33000 Bordeaux, France., Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier de la Côte Basque (CHCB), Centre hospitalier universitaire de Nantes (CHU Nantes), CHU Pontchaillou [Rennes], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Département d'Oncologie et Hématologie [Strasbourg], Les Hôpitaux Universitaires de Strasbourg (HUS), Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne (UCA), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département d'Hématologie Clinique (BREST - Hémato Clinique), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Université de Montpellier (UM), Service d’Hématologie [Institut Paoli Calmettes, Marseille], Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Innate Immunity and Immunotherapy (CRCINA-ÉQUIPE 7), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), and Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)

Subjects
0301 basic medicine, Oncology, Male, Cancer Research, medicine.medical_specialty, NPM1, Karyotype, [SDV.CAN]Life Sciences [q-bio]/Cancer, Risk profile, law.invention, 03 medical and health sciences, Cytogenetics, 0302 clinical medicine, Randomized controlled trial, law, Lomustine, Internal medicine, medicine, Biomarkers, Tumor, Idarubicin, Humans, Antineoplastic Agents, Alkylating, ComputingMilieux_MISCELLANEOUS, Chromosome Aberrations, business.industry, Cytarabine, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, Middle Aged, Prognosis, 3. Good health, Leukemia, Myeloid, Acute, 030104 developmental biology, 030220 oncology & carcinogenesis, Karyotyping, Mutation, Female, business, Nucleophosmin, medicine.drug
Abstract

International audience; We previously reported the benefit of lomustine addition to conventional chemotherapy in older acute myeloid leukemias with nonadverse chromosomal aberrations in the LAM-SA 2007 randomized clinical trial (NCT00590837). A molecular analysis of 52 genes performed in 330 patients included in this trial, 163 patients being treated with lomustine in combination with idarubicin and cytarabine and 167 without lomustine, identified 1088 mutations with an average of 3.3 mutations per patient. NPM1, FLT3, and DNMT3A were the most frequently mutated genes. A putative therapeutic target was identified in 178 patients (54%). Among five molecular classifications analyzed, the ELN2017 risk classification has the stronger association with the clinical evolution. Patients not treated with lomustine have an expected survival prognosis in agreement with this classification regarding the overall and event-free survivals. In strong contrast, lomustine erased the ELN2017 classification prognosis. The benefit of lomustine in nonadverse chromosomal aberrations was restricted to patients with RUNX1, ASXL1, TP53, and FLT3-ITDhigh/NPM1WT mutations in contrast to the intermediate and favorable ELN2017 patients. This post-hoc analysis identified a subgroup of fit elderly AML patients with intermediate cytogenetics and molecular markers who may benefit from lomustine addition to intensive chemotherapy.

Published
2021

9. EFFECT OF IMMUNOMODULATION FOR PERIPHERAL T-CELL LYMPHOMA IN RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT:A SFGM-TC STUDY ON 64 PATIENTS: PH-O112

Author

Mamez, A.-C., Levy, V., Chevallier, P., Vigouroux, S., Xhaard, A., Contentin, N., Mohty, M., Yakoub-Agha, I., Bulabois, C. E., Deconink, E., Lamy, T., huynh, A., Fegueux, N., Turlure, P., Maury, S., Beguin, Y., Bourhis, J.-H., Bilger, K., Bay, J.-O., Guillerm, G., Suarez, F., Maillard, N., Rialland, F., Jubert, C., and Quoc, Nguyen S.

Published
2014

10. Therapeutic management of patients relapsing after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome: a large-scale study on behalf of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC): O154

Author

Guièze, R., Damaj, G., Robin, M., Mohty, M., Michallet, M., Tabrizi, R., Beguin, Y., Blaise, D., Roosweil, D., Bulabois, C.-E., Legrand, F., Huynh, A., Cornillon, J., Contentin, N., Suarez, F., Lioure, B., Maillard, N., Clément, L., Guillerm, G., Rubio, M.-T., Garnier, F., and Yakoub-Agha, I.

Published
2013

14. The survival after allogeneic stem cell transplantation for blast crisis chronic myelogenous leukaemia relies on disease status prior to transplant and on the EBMT score, in the tyrosine kinase inhibitors era: P1150

Author

Labussiere, H., Milpied, N., Socie, G., Yakoub-Agha, I., Mohty, M., Fegueux, N., Tilly, H., Blaise, D., Bordigoni, P., Bilger, K., Cordonnier, C., Dalle, J.-H., De Revel, T., Deconinck, E., Rio, B., Sirvent, A., Ifrah, N., Guillerm, G., Mialou, V., Buzyn, A., Huynh, A., Bay, J. O., Raus, N., Morisset, S., Michallet, M., and Nicolini, F.

Published
2011

21. Keep in mind quality of life: outcome of a 10-year series of post-transplant early relapses in childhood acute lymphoblastic leukemia A report from the GOCE, the Grand Ouest oncology study group for children in France

Author

Haro, S., Tavenard, A., Rialland, F., Taque, S., Guillerm, G., Blouin, P., Esvan, M., Pellier, I., Gandemer, V, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Centre hospitalier universitaire de Nantes (CHU Nantes), Centre d'investigation clinique en cancérologie (CI2C), CHRU Brest - Service d'Hématologie (CHU-Brest-Hemato), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Institut de Génétique et Développement de Rennes (IGDR), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Jonchère, Laurent, Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
Early, [SDV.CAN] Life Sciences [q-bio]/Cancer, Hematopoietic stem cell transplantation, [SDV.CAN]Life Sciences [q-bio]/Cancer, Relapse, Children, Lymphoblastic leukemia
Abstract

International audience; Relapses of acute lymphoblastic leukemia (ALL) early after hematopoietic stem cell transplantations in children are uncommon but associated with a very poor prognosis. Whereas there are no current recommendations for the management of these relapses, the children's quality of life is an important issue. We studied the outcomes, including 1-year overall survival, complete remission, and quality of life, of 19 children with ALL who relapsed within the first year after their transplantation treated in the 5 participating centers between 2000 and 2011 Patients were distributed as follows: supportive care only (group A), outpatient treatment (mainly steroid and vincristine, group B), or intensive inpatient treatment (group C). There were no significant differences in 1-year overall survival (31.5% for the entire cohort) or remission rate for time between transplantation and relapse (< 6 months or 6 to 12 months), transplantation or disease characteristics, or treatment group. However, time spent in hospital (for treatment and complications) significantly differed between treatment groups B and C (20.8% ± 13.0 versus 59.1% ± 32.9, respectively; P < .05). No differences in organ toxicities, school attendance, or Lansky scores were found between treatment groups. Our sample size-limited data indicate, in a prepersonalized medicine era, that children treated with steroid and vincristine have the same prognosis as those treated with intensive therapy, but they may benefit from improved quality of life. Nevertheless, new therapeutic strategies are required and future prospective trials would help to establish recommendations.

Published
2016

23. Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

Author

Mamez, A-C, primary, Lévy, V, additional, Chevallier, P, additional, Blaise, D, additional, Vigouroux, S, additional, Xhaard, A, additional, Fegueux, N, additional, Contentin, N, additional, Beguin, Y, additional, Ifrah, N, additional, Bulabois, C-E, additional, Suarez, F, additional, Yakoub-Agha, I, additional, Turlure, P, additional, Deconink, E, additional, Lamy, T, additional, Cahn, J Y, additional, Huynh, A, additional, Maury, S, additional, Fornecker, L M, additional, Ouzegdouh, M, additional, Bay, J-O, additional, Guillerm, G, additional, Maillard, N, additional, Michallet, M, additional, Malfuson, J-V, additional, Bourhis, J-H, additional, Rialland, F, additional, Oumedaly, R, additional, Jubert, C, additional, Leblond, V, additional, Boubaya, M, additional, Mohty, M, additional, and Nguyen, S, additional

Published
2015
Full Text
View/download PDF

29. The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest

Author

Ben Abdelali, R., primary, Asnafi, V., additional, Petit, A., additional, Micol, J.-B., additional, Callens, C., additional, Villarese, P., additional, Delabesse, E., additional, Reman, O., additional, Lepretre, S., additional, Cahn, J.-Y., additional, Guillerm, G., additional, Berthon, C., additional, Gardin, C., additional, Corront, B., additional, Leguay, T., additional, Bene, M.-C., additional, Ifrah, N., additional, Leverger, G., additional, Dombret, H., additional, and Macintyre, E., additional

Published
2013
Full Text
View/download PDF

30. P-212 Therapeutic management of MDS patients relapsing after allo-SCT: A large-scale study on behalf of the SFGM-TC

Author

Guièze, R., primary, Damaj, G., additional, Robin, M., additional, Mohty, M., additional, Michallet, M., additional, Tabrizi, R., additional, Beguin, Y., additional, Blaise, D., additional, Roosweil, D., additional, Bulabois, C.E., additional, Legrand, F., additional, Huynh, A., additional, Cornillon, J., additional, Contentin, N., additional, Suarez, F., additional, Lioure, B., additional, Maillard, N., additional, Clément, L., additional, Guillerm, G., additional, Rubio, M.T., additional, Garnier, F., additional, and Yakoub-Agha, I., additional

Published
2013
Full Text
View/download PDF

31. Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Author

Marcais, A., primary, Porcher, R., additional, Robin, M., additional, Mohty, M., additional, Michalet, M., additional, Blaise, D., additional, Tabrizi, R., additional, Clement, L., additional, Ceballos, P., additional, Daguindau, E., additional, Bilger, K., additional, Dhedin, N., additional, Lapusan, S., additional, Bay, J.-O., additional, Pautas, C., additional, Garban, F., additional, Ifrah, N., additional, Guillerm, G., additional, Contentin, N., additional, Bourhis, J.-H., additional, Agha, I. Y., additional, Bernard, M., additional, Cornillon, J., additional, and Milpied, N., additional

Published
2013
Full Text
View/download PDF

43. MELPHALAN-PREDNISONE-THALIDOMIDE (MP-T) DEMONSTRATES A SIGNIFICANT SURVIVAL ADVANTAGE IN ELDERLY PATIENTS >75 YEARS WITH MULTIPLE MYELOMA COMPARED WITH MELPHALAN-PREDNISONE (MP) IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, IFM01/01

Author

Hulin, C., primary, Decaux, O., additional, Coiteux, V., additional, Rodon, P., additional, Pegourie, B., additional, Benboubker, L., additional, Gagneux, L., additional, Dib, M., additional, Voillat, L., additional, Guillerm, G., additional, and Moreau, P., additional

Published
2008
Full Text
View/download PDF

44. Hematopoietic Stem Cell Transplantation (HSCT) in Waldenström Macroglobulinemia (Wm), Update of the French Experience in 54 Cases.

Author

Dhedin, N., primary, Tabrizi, R., additional, Bulabois, P.E., additional, Le Gouill, S., additional, Coiteux, V., additional, Dartigeas, C., additional, Robin, M., additional, Huynh, A., additional, Larosa, F., additional, Cacheux, V., additional, Garnier, A., additional, Morel, P., additional, Kuentz, M., additional, Dreyfus, B., additional, Desablens, B., additional, Guillerm, G., additional, Pignon, B., additional, Rio, B., additional, Bilger, K., additional, Cabrespine, A., additional, Uzunov, M., additional, Bay, Jacques-Olivier, additional, Leblond, V., additional, and Tournihac, O., additional

Published
2007
Full Text
View/download PDF

45. Comparison of melphalan-prednisone-thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01–01 trial

Author

Hulin, C., primary, Virion, J., additional, Leleu, X., additional, Rodon, P., additional, Pegourie, B., additional, Benboubker, L., additional, Doyen, C., additional, Dib, M., additional, Guillerm, G., additional, and Moreau, P., additional

Published
2007
Full Text
View/download PDF

46. Balise intelligente pour mesure scientifique

Author

Guillerm, G

Subjects
Plate tectonics, Acoustic equipment, Marine technology
Abstract

MORS ENVIRONNEMENT has developed for the University of Hawaii a new system, SI 4X1-3, for study of movement of tectonic plate. In a single unit are gathered an acoustic rangemeter, a data acquisition unit (for 8 external sensors), a long range telemetry, and a power pack for 6 to 10 years life. The surface unit is a standard 16 frequencies RM 201 "OCEANO INSTRUMENTS" rangemeter. The programmation, the data transmission control, and the exploitation of the measures are done with a compatible IBM/AT. This system includes the know-how of SUBER and OCEANO INSTRUMENTS, and finds today a very large application field: Control and command of instrumented closing pigs; Seawater quality control without buoys and transmission up to 8 km; Corrosion control on platform and pipeline; Control and command of BOP, Christmas tree of other underwater system; High accuracy positioning for submersible (resolution of plus or minus 1 cm).

Published
1990

47. Major Superiority of Melphalan - Prednisone (MP) + Thalidomide (THAL) over MP and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients with Multiple Myeloma.

Author

Facon, Thierry, primary, Mary, J.Y., primary, Hulin, C., primary, Benboubker, L., primary, Attal, M., primary, Renaud, M., primary, Harousseau, J.L., primary, Pegourie, B., primary, Guillerm, G., primary, Chaleteix, C., primary, Dib, M., primary, Voillat, L., primary, Maisonneuve, H., primary, Troncy, J., primary, Dorvaux, V., primary, Monconduit, M., primary, Martin, C., primary, Casassus, P., primary, Jaubert, J., primary, Jardel, H., primary, Kolb, B., primary, and Bauters, F., primary

Published
2005
Full Text
View/download PDF

48. A Multicenter Prospective Randomized Study Testing Non-Inferiority of Thalidomide 100 mg/day as Compared with 400 mg/day in Patients with Refractory/Relapsed Multiple Myeloma: First Results of the Final Analysis of the IFM 01-02 Study.

Author

Yakoub-Agha, Ibrahim, primary, Hulin, C., primary, Doyen, C., primary, Benboubker, L., primary, Voillat, L., primary, Bouabdallah, K., primary, Guillerm, G., primary, Moreau, P., primary, Maloisel, F., primary, Stoppa, A.M., primary, Pegourie, B., primary, Rodon, P., primary, Dib, M., primary, Casassus, P., primary, Slama, B., primary, Voog, E., primary, Jardel, H., primary, Collet, P., primary, Wettervald, M., primary, Peny, A.M., primary, Mineur, P., primary, Duguet, C., primary, Zerbib, R., primary, Facon, T., primary, and Mary, J.Y., primary

Published
2005
Full Text
View/download PDF

49. Blockade of p110delta Isoform Activity of Phosphoinositide 3-Kinase Inhibits Blast Cell Proliferation in Acute Myeloblastic Leukemia.

Author

Bouscary, D., primary, Bardet, V., primary, Sujobert, P., primary, Cornillet-Lefebvre, P., primary, Hayflick, J. S., primary, Prie, N., primary, Verdier, F., primary, Vanhaesebroeck, B., primary, Muller, O., primary, Pesce, F., primary, Ifrah, N., primary, Berger, M. Hunault, primary, Bertho, C., primary, Guillerm, G., primary, Villemagne, B., primary, Audhui, B., primary, Solary, E., primary, Witz, F., primary, Harousseau, J. L., primary, Himberlin, C., primary, Lamy, T., primary, Lioure, B., primary, Bene, M. C., primary, Cahn, J. Y., primary, Dreyfus, F., primary, Mayeux, P., primary, and Lacombe, C., primary

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results